Sara van den Berg

40 Chapter 2 41. Wijnans, L. and B. Voordouw, A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses, 2016. 10(1): p. 2-8. 42. Wang, G.C., et al., T-cell receptor alphabeta diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med, 2012. 4(128): p. 128ra42. 43. Derhovanessian, E., et al., Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine, 2013. 31(4): p. 685-90. 44. Huang, K.A., et al., Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time. Sci Rep, 2017. 7: p. 40027. 45. Castilla, J., et al., Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill, 2013. 18(5). 46. Reed, R.G., R.N. Greenberg, and S.C. Segerstrom, Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade. Brain Behav Immun, 2017. 61: p. 14-20. 47. Chen, W.H., et al., Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine, 2012. 30(28): p. 4240-8. 48. Gostic, K.M., et al., Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science, 2016. 354(6313): p. 722-726. 49. Ann, J., et al., Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. J Clin Virol, 2012. 53(1): p. 88-92. 50. Orange, J.S., W. Du, and A.R. Falsey, Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses. Front Immunol, 2015. 6: p. 431. 51. Wertheimer, A.M., et al., Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T-cell subsets in humans. J Immunol, 2014. 192(5): p. 2143-55. 52. Wrammert, J., et al., Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med, 2011. 208(1): p. 181-93. 53. Centers for Disease, C. and Prevention, Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep, 2009. 58(19): p. 521-4.